Skip to content

LIFECODES Class I ID Typing Kit for use with Luminex 628200Recalls & reported problems

Immucor Gti Diagnostics, Inc. · LIFECODES Class I ID is a bead-based immunoassay used to qualitatively detect Panel Reactive HLA IgG antibodies (PRA) · Class U

Data updated Oct 18, 2026 from official FDA records · Editorial policy

Adverse event reports
1
Deaths reported
0
Injuries reported
0
Recalls naming it
0

Summary

The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 10888234400295), received between Jul 31, 2018 and Jul 31, 2018 — classified as 1 malfunction.

The most frequently reported specific device problem is “Off-Label Use” (1 report).

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.

Most reported problems

Device problems

  • Off-Label Use1

Patient problems

  • No Known Impact Or Consequence To Patient1

Recent adverse event reports

The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.

  • MalfunctionJul 31, 2018Off-Label Use; Off-Label Use

    COMPLAINT (B)(4) FOR LIFECODES CLASS I ID (628200), LOT # 3006385 WAS RECEIVED ON JULY 6, 2018. THE CUSTOMER REPORTS PATTERN OF POSITIVE RESULTS FOR HISTORICALLY NEGATIVE PATIENTS WHEN TESTED WITH CLASS I ID LOT 3006385. THE LAB'S SOP REQUIRES THAT ALL SAMPLES ARE PRE-TREATED WITH DTT (DITHIOTHREITOL) PRIOR TO TESTING. CUSTOMER HAS BEEN INFORMED THAT PRE-TREATMENT WITH DTT IS NOT A VALIDATED PROCESS AND IS CONSIDERED OFF-LABEL USE. IMMUCOR TECHNICAL SUPPORT REQUESTED THE CUSTOMER RUN THE SAMPLES NEAT (WITHOUT PRE-TREATMENT). CUSTOMER STATED THAT THEY WILL NOT PERFORM ANY TROUBLE-SHOOTING AT THIS TIME BUT WOULD LIKE IMMUCOR TO ADDRESS THIS ISSUE IN THEIR MANUFACTURING PROCESSES. CUSTOMER CONFIRMS NO PATIENT HARM. CUSTOMER REPORTED THE RESULTS BECAUSE THE ASSAY IS NOT USED AS A STANDALONE TEST. SIGNIFICANT CHANGES IN REACTIVITY ARE VERIFIED BY AN ALTERNATE ASSAY. REVIEW OF FINAL PRODUCT QUALITY CONTROL (FPQC) TESTING WAS PERFORMED, PRODUCT SPECIFICATIONS WERE MET.

    Patient problems: No Known Impact Or Consequence To Patient

    MAUDE report 7736238 ↗

Other Test,Qualitative,For Hla,Non-Diagnostic devices

All Test,Qualitative,For Hla,Non-Diagnostic devices →

Sources and updates

How reports and recalls are matched · Editorial policy · Report an error on this page